1033776-70-3Relevant academic research and scientific papers
Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors
Anandan, Sampath-Kumar,Do, Zung N.,Webb, Heather K.,Patel, Dinesh V.,Gless, Richard D.
scheme or table, p. 1066 - 1070 (2009/09/04)
Inhibition of soluble epoxide hydrolase has been proposed as a promising new pharmaceutical target for diseases involving hypertension and vascular inflammation. The most potent sEH inhibitors reported to date contain a urea or amide moiety as the central or 'primary' pharmacophore. We evaluated replacing the urea pharmacophore with other functional groups such as thiourea, sulfonamide, sulfonylurea, aminomethylene amide, hydroxyamide, and ketoamide to identify novel and potent inhibitors. The hydroxyamide moiety was identified as a novel pharmacophore affording potency comparable to urea.
SOLUBLE EPOXIDE HYDROLASE INHIBITORS
-
Page/Page column 90, (2008/12/06)
Disclosed are alpha keto amide and alpha hydroxy amide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.
